Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Untch, Michael; A. Fasching, Peter; E. Konecny, Gottfried; Hasmüller, Stephan; Lebeau, Annette; Kreienberg, R.; Camara, Oumar; Müller, Volkmar; du Bois, Andreas; Kühn, Thorsten; Stickeler, Elmar; Harbeck, Nadia; Höß, C.; Kahlert, S.; Beck, Thomas; Fett, W.; Mehta, Keyur; von Minckwitz, Gϋnter; Loibl, Sibylle

doi:10.1200/jco.2010.31.4930

Public

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Published in Journal of Clinical Oncology • Jul 26, 2011

Authors:

Michael Untch

Peter A. Fasching

Gottfried E. Konecny

Abstract

PURPOSE: To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. PATIENTS AND METHODS: Patients with centrally confirmed HER2-over...

Subject

Medicine

Trastuzumab

Epirubicin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!